Advanced Genomics is a personalized medicine company that specializes in pharmacogenomics and is dedicated to helping healthcare providers get the genetic information they need to determine the genetically appropriate medication(s) for individual patients. Advanced Genomics proprietary technology is based on pharmacogenomics— the study of the genetic factors that influence an individual’s response to drug treatments—as well as evidence-based medicine and clinical pharmacology. Working with our university researchers, the company’s mission is enabling and advancing the practice of Personalized Medicine. By combining our current scientific evidence and high-throughput DNA analysis technology, we bring an innovative industry leader approach to offering genetic testing services to our patients and physicians. The miGene™ test was developed in the Advanced Genomics clinical laboratory and is based on patented technology from collaborators from world renowned medical centers such as, Mayo Clinic, Johns Hopkins University, UT Health Science Center, and Penn State Medical Center.
Clinical Laboratory Improvement Amendments
The Centers for Medicare & Medicaid Services (CMS) regulates all laboratory testing (except research) performed on humans in the U.S. through the Clinical Laboratory Improvement Amendments (CLIA). The objective of the CLIA program is to ensure quality laboratory testing.